Kiromic BioPharma, Inc. (KRBP): Lienzo del Modelo de Negocio [Actualizado en Ene-2025]

En el reino de la inmunoterapia contra el cáncer, Kiromic Biopharma, Inc. (KRBP) emerge como una fuerza pionera, aprovechando su innovadora tecnología GNET para revolucionar el tratamiento personalizado del cáncer. Al mapear estratégicamente su modelo de negocio innovador, este pionero de biotecnología está listo para transformar la investigación oncológica a través de la ingeniería molecular de precisión, las asociaciones colaborativas y los enfoques terapéuticos innovadores que prometen redefinir cómo entendemos y combatemos el cáncer en su nivel genético más fundamental.

Kiromic BioPharma, Inc. (KRBP) - Modelo de negocios: asociaciones clave

Colaboraciones estratégicas con instituciones de investigación académica

Institución	Enfoque de investigación	Detalles de la asociación
Centro de cáncer de Anderson de la Universidad de Texas	Investigación de inmunoterapia	Acuerdo de investigación colaborativa para el desarrollo de la inmunoterapia contra el cáncer impulsado por la IA

Potencios de desarrollo farmacéutico de desarrollo farmacéutico

A partir de 2024, Kiromic Biofarma ha estado explorando asociaciones estratégicas de desarrollo farmacéutico para avanzar en su plataforma de inmunoterapia.

• Colaboración potencial con compañías farmacéuticas especializadas en investigación oncológica
• Discusiones con firmas de biotecnología para iniciativas de desarrollo de medicamentos conjuntos

Alianzas de la red de investigación de inmunoterapia

Red	Tipo de colaboración	Enfoque de investigación
Red de inmunoterapia contra el cáncer	Alianza de investigación	Estrategias de focalización inmunológica avanzada

Socios de tecnología de la plataforma de biotecnología

Kiromic BioPharma ha estado desarrollando asociaciones para mejorar sus plataformas de biotecnología impulsadas por la IA.

• Asociaciones de integración de tecnología de IA
• Acuerdos de colaboración de biología computacional

Gastos de desarrollo y desarrollo relacionados con la asociación total para 2023: $ 2.1 millones

Número de colaboraciones de investigación activa a partir del cuarto trimestre 2023: 3 asociaciones estratégicas

Kiromic BioPharma, Inc. (KRBP) - Modelo de negocio: actividades clave

Desarrollo de inmunoterapias personalizadas

A partir del cuarto trimestre de 2023, la biofarma kirómica se centró en desarrollar inmunoterapias personalizadas dirigidas a tipos de cáncer específicos.

Enfoque de investigación	Estado actual	Inversión
KRBP-T0 Inmunoterapia personalizada	Etapa preclínica	$ 3.2 millones asignados
Plataformas de edición de genes	Desarrollo activo	$ 2.7 millones invertidos

Investigación y desarrollo del tratamiento del cáncer

Los esfuerzos de I + D de Kiromic Biopharma se concentraron en estrategias avanzadas de tratamiento del cáncer.

• Gastos totales de I + D en 2023: $ 5.9 millones
• Áreas de enfoque de investigación: cáncer de pulmón, cáncer cerebral y tumores sólidos
• Número de proyectos de investigación en curso: 4

Ingeniería molecular y edición de genes

La compañía utilizó técnicas avanzadas de ingeniería molecular para el desarrollo terapéutico.

Tecnología	Etapa de desarrollo	Estado de patente
Plataforma de edición de genes CRISPR	Investigación avanzada	2 Patentes provisionales presentadas
Técnicas de inmunoterapia de precisión	Validación preclínica	1 patente pendiente

Gestión y ejecución del ensayo clínico

Las actividades de ensayos clínicos fueron críticas para la estrategia de investigación de Kiromic Biopharma.

• Ensayos clínicos activos en 2023: 2
• Presupuesto total de ensayos clínicos: $ 4.5 millones
• Colaboraciones de investigación institucional: 3 centros médicos académicos

Innovación de productos de biotecnología

La innovación continua siguió siendo una estrategia central para el desarrollo de productos de la empresa.

Área de innovación	Inversión	Resultado esperado
Plataforma de inmunoterapia	$ 3.6 millones	Prototipo terapéutico avanzado
Tecnologías de edición de genes	$ 2.9 millones	Enfoques de tratamiento novedosos

Kiromic BioPharma, Inc. (KRBP) - Modelo de negocio: recursos clave

Plataforma de tecnología de inmunoterapia GNET patentada

La plataforma de tecnología central de Kiromic BioPharma, GNET, representa un recurso clave crítico para el desarrollo de inmunoterapia de la compañía.

Aspecto tecnológico	Detalles específicos
Tipo de plataforma	Tecnología de ingeniería de redes genómicas (GNET)
Estado de patente	Patentes múltiples pendientes y otorgadas
Etapa de desarrollo	Fase de investigación preclínica avanzada

Equipo de investigación científica especializada

El equipo de investigación de la compañía comprende profesionales especializados en genómica e inmunoterapia.

Composición del equipo	Número
Personal de investigación total	Aproximadamente 22 empleados
Investigadores a nivel de doctorado	12 investigadores

Instalaciones avanzadas de laboratorio de biología molecular

• Ubicado en Houston, Texas
• Equipado con instrumentos de secuenciación genómica de última generación
• Laboratorio certificado de BioseFety Nivel 2 (BSL-2)

Cartera de propiedades intelectuales

Categoría de IP	Contar
Solicitudes de patentes totales	7 solicitudes de patentes
Patentes concedidas	3 patentes

Capacidades de investigación genómica y computacional

Kiromic Biofarma mantiene una sofisticada infraestructura computacional para la investigación genómica.

• Sistemas informáticos de alto rendimiento
• Software bioinformático avanzado
• Algoritmos de aprendizaje automático para análisis genómico

Kiromic BioPharma, Inc. (KRBP) - Modelo de negocio: propuestas de valor

Precisión Las inmunoterapias de cáncer dirigidas

Kiromic BioPharma se centra en desarrollar inmunoterapias de cáncer dirigidas con precisión utilizando tecnología de edición de genes CRISPR.

Tipo de terapia	Cáncer objetivo	Etapa de desarrollo
CRISPR-MOSTRADO CAR-T	Cáncer de pulmón	Preclínico
Inmunoterapia modificada por genes	Cáncer de ovario	Fase de investigación

Enfoques de tratamiento personalizados

Kiromic desarrolla inmunoterapias personalizadas con modificaciones genéticas específicas del paciente.

• Perfil genético para un tratamiento individualizado
• Ingeniería de células CAR-T específicas del paciente
• Dirección de precisión de mutaciones de células cancerosas

Soluciones innovadoras de edición de genes

La plataforma avanzada de edición de genes CRISPR dirigida a modificaciones genéticas complejas.

Tecnología	Capacidad de modificación	Nivel de precisión
CRISPR-CAS9	Edición de genes múltiples	Alta precisión

Posible avance en el tratamiento de oncología

El enfoque de Kiromic tiene como objetivo abordar las limitaciones en las inmunoterapias de cáncer actuales.

Mecanismos de focalización terapéutica avanzada

Desarrollo de estrategias de orientación sofisticadas para una mayor eliminación de células cancerosas.

Estrategia de orientación	Mecanismo	Eficacia potencial
Orientación múltiple	Modificación genética	Resistencia tumoral reducida

Kiromic BioPharma, Inc. (KRBP) - Modelo de negocio: Relaciones con los clientes

Compromiso directo con instituciones de investigación médica

A partir del cuarto trimestre de 2023, Kiromic Biopharma mantiene colaboraciones directas de investigación con 7 centros médicos académicos centrados en la investigación de inmuno-oncología.

Tipo de institución	Número de colaboraciones activas	Enfoque de investigación
Centros médicos académicos	7	Inmuno-oncología
Universidades de investigación	3	Medicina de precisión

Asociaciones científicas colaborativas

Kiromic ha establecido asociaciones estratégicas dirigidas a plataformas de descubrimiento de fármacos impulsadas por la IA.

• Asociaciones científicas activas totales: 5
• Acuerdos de colaboración de biología computacional: 3
• Plataformas de investigación impulsadas por IA: 2

Interacciones profesionales de la comunidad médica

Kiromic Biopharma participa en 12 conferencias anuales de oncología y simposios médicos a partir de 2024.

Tipo de conferencia	Participación anual	Método de compromiso
Conferencias oncológicas	8	Presentaciones de carteles
Simposia médica	4	Discusiones de panel científico

Comunicación de participantes del ensayo clínico

A partir de enero de 2024, Kiromic administra ensayos clínicos en curso con 127 participantes activos en múltiples estudios.

• Participantes de ensayos clínicos activos: 127
• Canales de comunicación: portales electrónicos de pacientes, contacto de coordinador clínico directo
• Frecuencia de seguimiento del paciente: evaluaciones trimestrales

Actualizaciones de desarrollo de investigación transparente

Kiromic proporciona actualizaciones trimestrales de inversores e investigaciones a través de múltiples canales de comunicación.

Actualizar el canal	Frecuencia	Tipo de información
Presentaciones de inversores	Trimestral	Progreso financiero y de investigación
Publicaciones científicas	By-anualmente	Resultados de la investigación
Actualizaciones del sitio web corporativo	Mensual	Hitos de investigación

Kiromic Biopharma, Inc. (KRBP) - Modelo de negocios: canales

Presentaciones de conferencias científicas

A partir del cuarto trimestre de 2023, Kiromic Biofarma participó en 3 principales conferencias de oncología e inmunoterapia, incluida la reunión anual de la Asociación Americana de Investigación del Cáncer (AACR).

Conferencia	Tipo de presentación	Fecha
Reunión anual de AACR	Póster	Abril de 2023
Sociedad de Inmunoterapia de Cáncer (SITC)	Plataforma de investigación	Noviembre de 2023

Publicaciones de revistas médicas revisadas por pares

En 2023, Kiromic publicó 2 artículos revisados ​​por pares en revistas científicas.

• Publicado en Investigación de Inmunología del Cáncer
• Publicado en Journal of Immunotherapy

Alcance de la industria farmacéutica directa

Kiromic se dedicó a 7 socios farmacéuticos potenciales en 2023 para posibles oportunidades de colaboración y licencia.

Compañía farmacéutica	Tipo de interacción	Enfoque potencial
Gran compañía farmacéutica A	Discusión inicial	Inmunoterapia impulsada por IA
Oncología especialidad de la empresa B	Exploración de licencias	Plataforma patentada de KRBP

Plataformas de comunicación científica digital

Kiromic mantiene la presencia digital activa en 3 plataformas de comunicación científica primaria.

• Red científica de LinkedIn
• Red de Professional de InvestigateGate
• Sección científica del sitio web de la empresa

Comunicaciones de inversionistas y partes interesadas

En 2023, Kiromic realizó 4 eventos de relaciones con inversores y llamadas de conferencia.

Tipo de evento	Frecuencia	Recuento de participantes
Llamada de ganancias trimestrales	4 veces	Aproximadamente 50-75 participantes
Presentación del inversor	2 veces	100-150 asistentes

Kiromic BioPharma, Inc. (KRBP) - Modelo de negocio: segmentos de clientes

Instituciones de investigación de oncología

A partir del cuarto trimestre de 2023, Kiromic Biofarma se dirige a 127 instituciones de investigación de oncología especializada en América del Norte.

Tipo de institución	Número de clientes potenciales	Presupuesto de investigación anual
Centros de cáncer designados por NCI	71	$ 3.2 mil millones
Centros médicos académicos	56	$ 2.7 mil millones

Compañías farmacéuticas

Kiromic se dirige a 42 compañías farmacéuticas con programas de investigación inmuno-oncológica.

• Las 20 principales compañías farmacéuticas globales con enfoque oncológico
• Empresas de biotecnología especializadas en inmunoterapia
• Organizaciones de investigación farmacéutica de tamaño mediano

Centros de tratamiento del cáncer

Clasificación central	Centros totales	Penetración potencial del mercado
Centros de cáncer integrales	51	38%
Centros de cáncer comunitario	1,500	12%

Laboratorios de investigación académica

La cobertura del mercado incluye 238 laboratorios de investigación académica centrados en la inmunogenómica.

• Universidades de investigación con programas de oncología dedicados
• Centros de investigación genómicos
• Laboratorios de medicina traslacional

Inversores de biotecnología

Categoría de inversionista	Número de inversores potenciales	Capacidad de inversión estimada
Empresas de capital de riesgo	87	$ 1.6 mil millones
Inversores de capital privado	53	$ 2.3 mil millones

Kiromic BioPharma, Inc. (KRBP) - Modelo de negocio: Estructura de costos

Gastos de investigación y desarrollo

Para el año fiscal que finalizó el 31 de diciembre de 2022, Kiromic Biopharma reportó gastos de I + D de $ 8,7 millones.

Año fiscal	Gastos de I + D
2022	$ 8.7 millones
2021	$ 7.3 millones

Inversiones de ensayos clínicos

Las inversiones de ensayos clínicos de la compañía para 2022 totalizaron aproximadamente $ 5.2 millones, centrándose en programas de inmuno-oncología.

Adquisición de personal y talento científico

Categoría de personal	Costo anual
Personal científico	$ 3.5 millones
Personal administrativo	$ 1.8 millones

Mantenimiento de equipos y tecnología de laboratorio

Los costos totales de mantenimiento de equipos y tecnología para 2022 fueron de $ 2.1 millones.

• Equipo de biotecnología especializada: $ 1.3 millones
• Infraestructura tecnológica: $ 0.8 millones

Costos de protección de propiedad intelectual

Los gastos anuales de protección de la propiedad intelectual fueron de $ 650,000 en 2022.

Categoría de protección de IP	Costo anual
Presentación de patentes	$450,000
Consulta legal	$200,000

Estructura de costos operativos totales para 2022: $ 20.25 millones

Kiromic BioPharma, Inc. (KRBP) - Modelo de negocios: flujos de ingresos

Licencias potenciales de tecnologías de inmunoterapia

A partir del cuarto trimestre de 2023, Kiromic BioPharma no ha informado ningún ingreso activo de licencia de sus tecnologías de inmunoterapia.

Financiación de la subvención de investigación

Año	Fuente de subvenciones	Cantidad
2022	NIH Investigación de innovación de pequeñas empresas (SBIR)	$299,980
2023	Financiación total de la subvención de investigación	$336,000

Comercialización de productos terapéuticos futuros

No se reportaron ingresos comerciales a partir de 2024. Los productos de la tubería todavía están en etapas de desarrollo clínico y clínico.

Acuerdos de asociación estratégica

• No hay acuerdos de asociación estratégica activa que generen ingresos a partir de 2024
• Colaboraciones de investigación continuas sin rendimientos financieros inmediatos

Pagos potenciales de hitos de colaboraciones farmacéuticas

Estado de colaboración	Rango de pago de hito potencial
Posibles colaboraciones futuras	$ 0 - $ 500,000 estimado

Ingresos totales de la compañía para 2023: $336,000

Kiromic BioPharma, Inc. (KRBP) - Canvas Business Model: Value Propositions

You're looking at the core value Kiromic BioPharma, Inc. is trying to deliver with its platform, especially when you compare it to the established, but cumbersome, autologous (patient-specific) cell therapies. The main draw here is speed and accessibility for serious conditions.

The primary offering is Deltacel™, which is an allogeneic, off-the-shelf Gamma Delta T-cell (GDT) therapy. This means it's ready to go from the donor, not custom-made for each patient, which directly addresses the 'faster patient access' proposition.

The clinical focus is squarely on solid tumors, an area where CAR-T has historically struggled. Specifically, the initial target is metastatic non-small cell lung cancer (NSCLC), which makes up about 80% to 85% of all lung cancer cases.

This approach gained significant regulatory validation. Kiromic BioPharma secured FDA Fast Track Designation in August 2024 for Deltacel™ when used with low-dose radiation therapy for metastatic NSCLC patients who have already progressed on 2 or more prior lines of standard-of-care treatment.

Here's a quick look at the early clinical data supporting this value, keeping in mind the trial is ongoing with an estimated completion date of January 2027:

• Average Progression-Free Survival (PFS) of 4.8 months (range, 2-8) among 5 evaluable patients from Part 1 data reported on August 9, 2024.
• One patient showed a 32% Decrease in Tumor Volume eight months post-treatment (reported December 12, 2024).
• Another patient reached 10-Month Progression-Free Survival (reported February 18, 2025).
• The trial reported No dose-limiting toxicities for patients completing the full course of therapy.

The engine driving the discovery of these targets is the proprietary DIAMOND® AI 2.0 target discovery engine. While general industry data suggests AI can reduce drug discovery costs by up to 40% and slash timelines to 12-18 months, Kiromic BioPharma is using this to create high-precision immuno-oncology candidates.

The cost and logistics proposition is where the allogeneic nature really shines against the competition. You can see the contrast clearly when you map the known issues of autologous treatments against the intended benefits of Kiromic BioPharma's platform:

Value Proposition Aspect	Autologous Therapy Challenge	Kiromic BioPharma Deltacel (Allogeneic) Value
Manufacturing Cost	Exorbitant production costs, limiting accessibility.	Aims to mitigate high costs through scalable, donor-derived production.
Manufacturing Timeline	Long time needed to process patient cells, delaying treatment.	Off-the-shelf availability for faster patient access.
Solid Tumor Targeting	Limited efficacy in solid tumors remains a significant challenge.	Designed to exploit natural potency of GDT cells to target solid cancers.

To give you some context on the investment required to support this development, the clinical trials expenses for Deltacel-01 rose to $8.1 million for the year ended December 31, 2024, contributing to a reported net loss of $26.9 million for that same fiscal year. The company raised $18.4 million through financing activities to support operations, though it noted insufficient cash resources beyond March 2025.

Kiromic BioPharma, Inc. (KRBP) - Canvas Business Model: Customer Relationships

You're looking at the relationships Kiromic BioPharma, Inc. maintained with its key external stakeholders, which, for a clinical-stage biotech, are primarily investigators, regulators, and capital providers. These relationships were critical, especially given the company's financial position leading into 2025.

High-touch, direct collaboration with clinical investigators and sites

The core of the customer relationship, in the clinical sense, involved the investigators and sites running the Deltacel-01 Phase 1 study. This required close, direct interaction to ensure protocol adherence and data integrity. The company was actively working to expand this network, having expected to activate a fifth clinical trial site on August 30, 2024.

The relationship with the medical community was built on the preliminary data generated from the Deltacel therapy in combination with low-dose radiation for metastatic non-small cell lung cancer (NSCLC).

Here's a look at the clinical milestones that underpinned these collaborations:

Metric	Value/Status	Date Context
Product Candidate	Deltacel (KB-GDT-01)	Ongoing Phase 1
Tumor Volume Decrease (Patient 4)	32%	Eight Months Post-Treatment (Reported Dec 2024)
Progression-Free Survival (Patient 4)	10-Month	Reported Dec 2024
Preliminary Tumor Reduction (First Patient)	6.6%	Reported March 2024
Total Product Candidates	3 (Deltacel, Isocel, Procel)	Pre-Bankruptcy

Dedicated investor relations for capital raising and market communication

For a company operating with substantial doubt about its ability to continue as a going concern, investor relations was a survival function. The focus was squarely on capital raising to fund operations, which were heavily weighted toward clinical expenses. For the year ended December 31, 2024, Kiromic BioPharma, Inc. reported net losses of $26.9 million.

The company actively engaged investors, for instance, by participating in the OTC Markets' Life Science Investor Forum on March 7, 2024. The financial activities show the reliance on external funding sources.

Key financial interactions defining this relationship included:

• Cash provided by financing activities for the nine months ended September 30, 2024: $16,000,000.
• Gross proceeds from a private placement in August 2024: $2,000,000 via a note bearing 25% interest.
• Total financing raised to support operations (as of Feb 2025 filing): $18.4 million.
• Cash and cash equivalents as of September 30, 2024: $3,056,000.
• The company acknowledged that cash resources were insufficient to meet obligations beyond March 2025.

The IR contact listed for the company was Alliance Advisors IR, with Tirth T. Patel as the contact.

Regulatory engagement with the U.S. FDA (e.g., Fast Track process)

Regulatory engagement was a high-stakes relationship, especially following past disclosure issues. A major positive milestone was the U.S. Food and Drug Administration (FDA) granting Fast Track designation to Deltacel in August 2024. This designation is designed to expedite development and review for serious conditions filling an unmet need, allowing for more frequent communication with the FDA.

This positive engagement contrasts with prior regulatory friction. The company settled an SEC investigation in December 2024 related to the non-disclosure of clinical holds placed on IND applications in June 2021. The SEC did not impose a civil penalty due to the company's self-reporting, prompt remediation, and cooperation.

The Fast Track status for Deltacel was specifically for its use in combination with low-dose radiation therapy for metastatic NSCLC patients who progressed on at least two lines of standard of care therapy.

Scientific and medical community outreach via publications and conferences

Outreach to the scientific community centered on presenting clinical data and highlighting the underlying technology platform. The company's proprietary DIAMOND® artificial intelligence (AI) 2.0 target discovery engine was a key asset discussed in these forums.

The scale of the data underpinning this platform was cited as a relationship-building asset with the scientific community.

Key metrics related to scientific outreach and platform development included:

• Data collected into the DIAMOND® platform: Over two billion data points (as of March 2024).
• Clinical Trial Expenses for 2024: $8.1 million.
• Research and development expenses for 2024: $6.9 million.
• The platform supports 3 product candidates: Deltacel, Isocel, and Procel.

The company's management, including the CEO, participated in investor forums to communicate these scientific developments directly to the market.

Kiromic BioPharma, Inc. (KRBP) - Canvas Business Model: Channels

You're looking at the Channels for Kiromic BioPharma, Inc. (KRBP) as of late 2025. Honestly, the reality of the situation dictates the current channel strategy, which is far from a typical commercialization roadmap. The most significant financial and operational event defining this period is the filing of a voluntary petition for relief under Chapter 7 of Title 11 of the United States Code on March 21, 2025, in the United States Bankruptcy Court for the District of Delaware.

Clinical trial sites (e.g., Texas Oncology, Virginia Oncology Associates)

The activation of clinical trial sites, which was an active channel focus in 2023 for the Deltacel (KB-GDT-01) Phase 1 trial in non-small cell lung cancer (NSCLC), is effectively suspended or in the process of being terminated due to the Chapter 7 filing on March 21, 2025. Any remaining site relationships would now be managed through the bankruptcy proceedings for asset disposition or contract wind-down, not patient enrollment.

• Last known trial focus: Phase 1 for Deltacel in NSCLC.
• Operational status: Governed by Chapter 7 proceedings as of March 21, 2025.

Scientific publications and presentations at oncology conferences

For a company in Chapter 7 liquidation, presenting new data is not a near-term channel. However, the scientific community where Kiromic BioPharma, Inc. would have aimed to present its data on Gamma Delta T-cell therapy remains active. For instance, the Society of Hematologic Oncology (SOHO) Annual Meeting in September 2025 was expected to draw more than 3,800 participants. Other relevant forums included the IASLC World Conference on Lung Cancer in September 2025 and the Summit for Novel Therapeutics in Oncology & Precision Medicine in Cancer (STOP Cancer) in late September 2025.

The primary channel for scientific communication shifts from presenting new trial data to managing the scientific record related to their proprietary DIAMOND® AI platform and cell therapy candidates.

Investor relations portal and SEC filings for public communication

The official channel for public and investor communication is now dominated by bankruptcy-related disclosures. The company's CIK identifier is 0000071691. The critical filing was the Form 8-K reporting the Bankruptcy or Receivership on March 21, 2025. Prior to this, the company was filing quarterly reports, such as the 10-Q for the quarter ending March 31, 2025, filed on May 7, 2025. The July 2021 follow-on public offering, which raised $40 million to fund prospective clinical trials, is now a historical financial data point relevant to the company's wind-down.

Communication Channel Element	Key Identifier/Date/Amount
CIK Number	0000071691
Chapter 7 Filing Date	March 21, 2025
Bankruptcy Court Location	District of Delaware
Last Reported Offering Amount (Historical Context)	$40 million (July 2021)

Direct sales force (future, post-commercialization)

The deployment of a direct sales force for commercialization is not a current or future channel for Kiromic BioPharma, Inc. given the Chapter 7 status as of March 21, 2025. In the biopharma industry generally, successful commercialization requires deploying sales forces supported by Pharma CRM software to manage relationships with healthcare professionals (HCPs). For context, industry benchmarks suggest that successful commercialization must maximize returns during the approximately 7 to 10 years of patent protection remaining after launch, a phase Kiromic BioPharma, Inc. will not reach for its current pipeline assets.

• Post-commercialization sales force: Not applicable due to bankruptcy.
• Industry benchmark for patent life post-launch: 7 to 10 years.

Finance: Review the final asset disposition schedule from the Chapter 7 trustee by next Tuesday.

Kiromic BioPharma, Inc. (KRBP) - Canvas Business Model: Customer Segments

You're looking at the core groups Kiromic BioPharma, Inc. (KRBP) needs to satisfy to move its cell therapy pipeline forward, especially as of late 2025.

The most immediate customer segment involves the patients themselves, specifically those with advanced disease who have exhausted other options.

• Patients with stage 4 metastatic or locally-advanced non-small cell lung cancer (NSCLC) failing standard therapies are the target for the Deltacel-01 Phase 1 clinical trial.

The clinical side represents the next layer of customer engagement, where the product is tested and administered.

• The Deltacel-01 trial has involved multiple clinical sites, including Beverly Hills Cancer Center (BHCC), Clinical Research Advisors Koreatown, and Virginia Oncology Associates.
• The University of Arizona Cancer Center was activated as the fifth clinical trial site in September 2024.

Funding this development is critical, making investors a key segment, even if the company has acknowledged substantial doubt about its ability to continue as a going concern beyond March 2025. The company was actively seeking additional financing.

Future pharmaceutical partners are the ultimate commercial customers for licensing or co-development deals, which are essential for market access and revenue generation.

Here's a quick look at the quantifiable data points related to these segments as reported in early 2025 filings and press releases:

Customer Segment	Key Metric	Reported Value/Amount	Date Context
Patients (Deltacel-01 Trial)	Number of Patients Enrolled/Treated (Minimum)	9 patients treated/enrolled as of January 21, 2025
Patients (Deltacel-01 Trial)	Tumor Volume Reduction (Patient 1)	33.33% reduction at 12-month follow-up
Patients (Deltacel-01 Trial)	Tumor Volume Reduction (Patient 7)	9.5% reduction at two-month follow-up
Clinical Sites/Investigators	Number of Activated Trial Sites (Minimum)	5 sites activated as of September 2024
Institutional Investors	Financing Raised (Convertible Notes)	$18.4 million raised to support operations
Institutional Investors	Reported Institutional Filers (13D/G or 13F)	1 institutional owner reported
Future Partners	Prior Equity Offering Amount	$40 million raised in a July 2021 offering

The success of current and future license and collaboration agreements is a stated factor in the company's outlook.

Finance: draft 13-week cash view by Friday.

Kiromic BioPharma, Inc. (KRBP) - Canvas Business Model: Cost Structure

You're looking at the core expenses driving Kiromic BioPharma, Inc.'s operations as they push their cell therapy candidates through clinical stages. For a pre-commercial biotech, the cost structure is almost entirely weighted toward discovery, development, and compliance. The numbers from the fiscal year ended December 31, 2024, paint a clear picture of where the cash burn is concentrated.

The primary cost drivers are heavily skewed toward the science. For FY 2024, Research and Development (R&D) expenses totaled $6.9 million, a slight dip from $7.0 million the prior year, showing a tight focus on their Deltacel product candidate development. However, the real spike is in the clinical execution. Significant clinical trial expenses hit $8.1 million in FY 2024, a substantial increase from $2.7 million the year before, directly tied to activating the Deltacel-01 trial. That's where the money goes when you're testing a therapy in humans; you can't really skimp there.

General and administrative (G&A) costs, which cover the overhead of running the company-salaries, rent, professional fees-were $8.9 million for FY 2024. That's down from $10.3 million previously, suggesting some belt-tightening on the non-R&D side, likely through a reduction in professional and legal fees. Still, the total operating expenses for the year were $23.77 million, leading to a net loss of $26.9 million for the period. That's the cost of keeping the lights on and the trials running.

Here's a quick look at the main operating expense categories for the fiscal year ending December 31, 2024:

Expense Category	FY 2024 Amount (in millions)
Research and Development (R&D)	$6.9
Clinical Trial Expenses	$8.1
General and Administrative (G&A)	$8.9
Total Operating Expenses	$23.77

The physical infrastructure supporting this work is also a cost center. Kiromic BioPharma, Inc. maintains its Houston cGMP manufacturing facility. While specific annual maintenance costs aren't itemized in the same way as R&D, the balance sheet shows the investment in the physical plant. As of December 31, 2024, Property, Plant, and Equipment stood at $4.31 million. You have to factor in the depreciation, utilities, and specialized staffing required to keep a current Good Manufacturing Practice (cGMP) site ready for potential future commercial production or advanced clinical supply.

Beyond the direct R&D and G&A spend, there are essential, recurring costs to protect the core assets. These include:

• Patent prosecution expenses to secure new intellectual property.
• Intellectual property maintenance fees to keep existing patents active.
• Costs related to regulatory filings and compliance activities.
• Stock-based compensation, which was $0.60 million for the year.

These fixed costs are non-negotiable for a company whose value is tied to its pipeline exclusivity. Finance: draft 13-week cash view by Friday.

Kiromic BioPharma, Inc. (KRBP) - Canvas Business Model: Revenue Streams

You're looking at the revenue side for Kiromic BioPharma, Inc. as of late 2025. Since this is a clinical-stage company, the current revenue picture is almost entirely non-operational, meaning it comes from capital markets rather than selling a product.

Zero product revenue (pre-commercial stage)

As of the end of fiscal year 2024, Kiromic BioPharma, Inc. has consistently reported zero revenue. This is typical for a company focused on developing its pipeline candidates, like Deltacel™, through clinical trials. The financial data from the annual report filed in February 2025 confirms this pre-commercial status, showing zero revenue for the year ended December 31, 2024. This zero revenue, coupled with widening net losses-which reached $26.9 million for the year ended December 31, 2024-is the financial signature of a company funding its research and development entirely through external capital. The company has reported zero revenue and negative gross profit in each year from 2021 through 2024.

Proceeds from financing activities (e.g., convertible notes, equity offerings)

The primary source of cash inflow for Kiromic BioPharma, Inc. is financing. This capital is essential to fund operations, especially the clinical trials for Deltacel™. The company actively sought and secured funds through debt instruments, primarily convertible notes, to bridge operational gaps. For instance, the nine months ending September 30, 2024, showed Cash provided by financing activities was $16,000,000. Separately, the annual report covering the fiscal year ended December 31, 2024, indicated the company raised $18.4 million through financing activities, mainly from issuing convertible notes to support operations. One specific transaction noted was the completion of a private placement on August 1, 2024, issuing a senior secured convertible promissory note for gross proceeds of $2,000,000, which carried a 25% per annum interest rate and was set to mature on August 1, 2025.

Here's a look at the financing activity reported around the 2024 period:

Financing Metric/Event	Amount (USD)	Reporting Period/Date
Cash Provided by Financing Activities	$16,000,000	Nine months ended September 30, 2024
Total Raised via Financing Activities (Convertible Notes)	$18.4 million	Fiscal Year Ended December 31, 2024
Gross Proceeds from Senior Secured Convertible Note	$2,000,000	Completed August 1, 2024
Exchange of Senior Convertible Notes into Preferred Stock (Non-cash)	$16,838,000	Reported in 2024 filings

The reliance on these activities highlights the ongoing need for capital, as the company faced substantial doubt about its ability to continue as a going concern without additional financing as of late 2024.

Potential future upfront payments from licensing or collaboration deals

As of late 2025, Kiromic BioPharma, Inc. has not publicly announced any realized upfront payments from licensing or collaboration deals for its pipeline assets. The focus has been on advancing Deltacel™ through its Phase 1 clinical trial, which received Fast-Track Designation from the FDA in August 2024. The potential for future revenue streams is tied directly to the success of this clinical advancement. The company's strategy involves developing its allogeneic Gamma Delta T-cell therapy platform, which could attract strategic partners interested in licensing rights for specific indications or geographies once positive data emerges from the ongoing Deltacel-01 trial.

Potential future milestone payments from strategic alliances

Milestone payments are contingent revenues tied to achieving specific development, regulatory, or commercial goals outlined in a partnership agreement. Currently, there are no reported active agreements that specify dollar amounts for future milestone payments. The potential exists for such payments upon:

• Successful completion of the Deltacel-01 Phase 1 trial, especially moving into Phase 2 or Phase 3.
• Achieving specific endpoints, such as progression-free survival targets, which were recently reported for Patient 4 at 10 months as of January 2025.
• Regulatory milestones, such as receiving Investigational New Drug (IND) clearance for other pipeline candidates like Isocel or Procel.

Future product sales of Deltacel™ and other pipeline candidates

Future product sales represent the ultimate, long-term revenue stream for Kiromic BioPharma, Inc., but these are entirely prospective. The company is developing Deltacel™ for stage 4 metastatic non-small cell lung cancer (NSCLC), which represents about 80% to 85% of all lung cancer cases. The realization of sales revenue depends on successfully navigating the remaining clinical trial phases, securing regulatory approval, and establishing manufacturing and commercialization capabilities. No specific sales forecasts or pricing data for Deltacel™ are available as of late 2025, given its status in the Phase 1 trial.

The company's pipeline includes:

• Deltacel™ (KB-GDT-01): Lead candidate, currently in the Deltacel-01 Phase 1 trial.
• Isocel: Another product candidate on the GDT platform.
• Procel: Another product candidate on the GDT platform.

The near-term financial action for you is tracking cash burn against the next financing round needed, as current resources are insufficient to fund operations beyond December 2024, according to a late 2024 filing. Finance: draft 13-week cash view by Friday.